Portal de Periódicos da CAPES

Chimeric DNA-RNA Hammerhead Ribozyme to Proliferating Cell Nuclear Antigen Reduces Stent-Induced Stenosis in a Porcine Coronary Model

1999; Lippincott Williams & Wilkins; Volume: 99; Issue: 5 Linguagem: Inglês

10.1161/01.cir.99.5.697

1524-4539

Aaron Frimerman, Peter J. Welch, Xiaomei Jin, Neal Eigler, Soonpin Yei, James S. Forrester, Hidehiko Honda, Raj Makkar, Jack R. Barber, Frank Litvack,

Glycosylation and Glycoproteins Research

Background —Stent-induced coronary restenosis is a major clinical and public health problem. Proliferating cell nuclear antigen (PCNA) is an important regulator of cell division, and blocking of its expression after angioplasty may limit intimal proliferation. Methods and Results —We cloned the porcine PCNA gene and constructed a chimeric hammerhead ribozyme to a segment of the gene with human homology. In vitro studies with both cultured porcine and human vascular smooth muscle cells demonstrated uptake of ribozyme within the nucleus and significant inhibition of cellular proliferation. The ribozyme was then delivered locally into pig coronaries in a stent model. At 30 days, histomorphometric analysis showed neointimal thickness of 0.51±0.20 mm in the ribozyme group versus 0.71±0.27 and 0.66±0.25 mm in stent controls and scrambled ribozyme control, respectively ( P =0.002, P =0.03). Quantitative angiographic analysis showed late loss of 1.4±0.5 mm for ribozyme versus 1.9±0.4 and 2.0±0.4 mm for the controls ( P =0.05 and P =0.02). Conclusions —Chimeric hammerhead ribozyme to PCNA inhibits smooth muscle cell proliferation in vitro and reduces both histomorphometric and angiographic restenosis in the porcine coronary stent model when delivered locally.